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ABSTRACT 28 
Misdiagnosis of enteric fever is a major global health problem resulting in patient mismanagement, 29 
antimicrobial misuse and inaccurate disease burden estimates. Applying a machine-learning algorithm 30 
to host gene expression profiles, we identified a diagnostic signature which could accurately 31 
distinguish culture-confirmed enteric fever cases from other febrile illnesses (AUROC>95%). 32 
Applying this signature to a culture-negative suspected enteric fever cohort in Nepal identified a 33 
further 12.6% as likely true cases. Our analysis highlights the power of data-driven approaches to 34 
identify host-response patterns for the diagnosis of febrile illnesses. Expression signatures were 35 
validated using qPCR highlighting their utility as PCR-based diagnostic for use in endemic settings. 36 
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Enteric fever, a disease caused by systemic infection with S. enterica serovars Typhi or Paratyphi A, 37 
accounts for 13.5 to 26.9 million illness episodes worldwide each year.1,2 In resource-limited tropical 38 
settings these infections are endemic and the accurate diagnosis of patients presenting with 39 
undifferentiated fever is challenging. 40 
Diagnostic tests for enteric fever rely on microbiological culture or detection of a serological response 41 
to infection, and are often unavailable or insufficiently sensitive and specific.3 Blood culture remains 42 
the reference standard against which new diagnostic tests are evaluated, and the sensitivity for this test 43 
can reach 80% under optimal conditions4 but low blood volumes and uncontrolled antibiotic use often 44 
result in decreased sensitive in the field. New diagnostic approaches are urgently needed to enable the 45 
accurate detection of enteric fever cases in endemic settings, to guide management of febrile patients, 46 
appropriate use of antimicrobials, and to identify populations likely to benefit from vaccine 47 
implementation. 48 
Most common tests used for acute infectious disease diagnosis employ methods to directly detect the 49 
disease-causing pathogen, either by culture, antigen detection or amplification of genetic material by 50 
PCR. An alternative approach is to identify a set of human host immune responses, which together 51 
may generate a specific pattern associated with individual infections or pathogens. With an increasing 52 
quantity of molecular host response data being generated by high-throughput methods ± including 53 
whole blood gene expression profiling ± differences in the activation status of the immune response 54 
network during infection may be a tractable diagnostic approach. Recently small sets containing 2-3 55 
genes have been described, the expression of which can accurately differentiate between viral or 56 
bacterial infection, and active or latent tuberculosis.5,6 Merging available well-characterised datasets 57 
derived from human clinical samples representative of a variety of fever-causing infections common 58 
in tropical settings presents an invaluable resource to identify host immune response patterns specific 59 
for enteric fever.  60 
As a human restricted infection, the development of enteric fever diagnostics has been hindered by the 61 
lack of reliable in vivo models. Using data from a series of controlled human infection models 62 
(CHIM)4,7 or S. Typhi or S. Paratyphi A infection, whole blood gene transcriptional responses were 63 
identified and then further characterised using samples collected from febrile patients in an endemic 64 
setting (Kathmandu, Nepal). Integrating these data with publically available human gene transcription 65 
datasets, we employed a machine learning algorithm to identify an expression signature that could 66 
accurately distinguish blood culture-confirmed EF cases in both the controlled environment (CHIM) 67 
and endemic setting from other febrile disease aetiologies and non-infected individuals (healthy 68 
controls).8-12 69 
  70 
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Results 71 
Transcriptional profiles in response to enteric fever are similar in challenge study and endemic 72 
cohorts 73 
We recently described the molecular response profile of acute enteric fever in individuals 74 
participating in the typhoid CHIM, which was characterized by innate immunity, inflammatory and 75 
interferon signalling patterns.13  76 
To compare responses to enteric fever occurring during natural infection in an endemic area, we 77 
generated transcriptional profiles in samples collected from culture-confirmed enteric fever patients 78 
(S. Typhi: µ13-67¶; S. Paratyphi: µ13-637¶, healthy community controls µ13-&75/¶ and 79 
febrile, culture-negative suspected enteric fever cases µ13-V()¶ recruited in Nepal (Kathmandu; 80 
6WXG\µ13¶) (Figure 1a). We detected significant differential expression (DE; FDR<0.05, 81 
FC±1.25) of 4,308 and 4,501 genes in enteric fever patients with confirmed S. Typhi (n=19) and S. 82 
Paratyphi (n=12) bacteraemia, respectively, when compared with healthy community controls (n=47; 83 
Figure 1b). Similar numbers of genes were differentially expressed in samples collected at the time of 84 
enteric fever diagnosis in healthy adult volunteers challenged with either S. Typhi (µT1-67¶) or S. 85 
Paratyphi (µ3-637¶) in a CHIM (Figure 1b).7,13 86 
As comparison of host responses at the gene level can be difficult to interpret, we performed Gene Set 87 
Enrichment Analysis (GSEA)14 of blood transcriptional modules (BTMs) as a conceptual framework 88 
to interpret the host responses in the context of biological pathways and themes.15 Overall, between 54 89 
and 74 BTMs were significantly enriched (BH adjusted p<0.01) in blood culture-confirmed enteric 90 
fever cases in the CHIM and natural infection and CHIM participants who did not develop enteric 91 
fever (measured at day 7 post-challenge - µQ'(Supplementary Table 1). The majority of BTMs 92 
enriched in cases from the enteric fever CHIM were also enriched in naturally infected cases from 93 
Nepal (56%-69, Supplementary Table 1±red squares). Positively enriched modules represented cell 94 
cycle (CCY), type I/II interferon and innate antiviral responses (IFN), dendritic cell (DC), innate 95 
immunity, inflammation and monocyte (Infl./Mono) signatures. In contrast, T cell (TC) signatures 96 
were down-regulated in patients with confirmed enteric fever, as we have previously described 97 
(Figure 1c-e).13 In addition a number of modules including inflammasome receptors (M53), 98 
monocyte enrichment (M118.0, M118.1, M81, M4.15, M23, M73, M64, S4) and inflammatory 99 
responses (M33) were significantly enriched in the CHIM but not in cases from Nepal. Single sample 100 
GSEA (ssGSEA) demonstrated the similar enrichment pattern for a selection of IFN and DC 101 
signatures between individuals with confirmed typhoid and paratyphoid fever in the CHIM and 102 
naturally infected cases (Figure 1f). Overall, we observed marked similarity in the gene transcription 103 
responses between acute enteric fever cases from the CHIM and an endemic setting in Nepal. 104 
 105 
 106 
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Responses of febrile, culture-negative samples in Nepal 107 
In culture-negative, suspected enteric fever patients µV()¶ from Nepal, we detected differential 108 
expression of 3,517 genes when compared with healthy community controls (Supplementary Figure 109 
1b). While we observed 2,843 genes as commonly expressed in all three Nepali patient cohorts 110 
(03NP-ST, 03NP-SPT and 03NP-sEF), an additional 582, 756 and 183 genes were uniquely expressed 111 
by subjects with confirmed S. Typhi, S. Paratyphi or suspected enteric fever, respectively 112 
(Supplementary Figure 1a&b). Unsupervised hierarchical clustering of these patients based on their 113 
expression of the 500 most variable genes in the Nepal cohort demonstrated clustering into three 114 
groups (Figure 1g): Group 1 contained mostly healthy control participants; Group 2 contained mostly 115 
patients with suspected enteric fever; and Group 3 contained a mixture of patients with suspected 116 
enteric fever, and blood culture-confirmed S. Typhi or S. Paratyphi infection.  117 
Using ssGSEA we observed a heterogeneous BTM enrichment pattern with broad variability in 118 
normalized enrichment scores across suspected enteric fever patients (depicted by the interdecile 119 
range; Supplementary Figure 1c). The most consistent positively or negatively enriched modules 120 
represented cell cycle, IFN, inflammatory responses, DC and some NK cell signatures (green cluster) 121 
and TC and BC related signatures (red cluster), respectively. In contrast, heterogeneous enrichment in 122 
which approximately half of participant samples demonstrated up or down regulation was observed in 123 
BTMs representing TC activation patterns, protein folding and metabolism (brown cluster), or in 124 
innate response and monocyte signatures (purple cluster) (Supplementary Figure 1c). These febrile 125 
patients were considered clinically to have enteric fever, and were therefore treated as such, however 126 
their heterogeneous gene transcription profiles suggest that any one of several different aetiologies 127 
may have precipitated hospital presentation. Further evidence to this is that in a recent RCT a higher 128 
proportion of culture-negative cases responded to fluoroquinolones rather than a 3rd generation 129 
cephalosporin, possibly due to the frequency of murine and scrub typhus in this population, however 130 
distinguishing between these infections is currently difficult.  131 
 132 
Multi-cohort data quality assessment 133 
In order to address the potential over-diagnosis of enteric fever and associated inappropriate 134 
antimicrobial use, we next aimed to identify a set of genes whose expression is able to differentiate 135 
enteric fever from other common febrile conditions found in tropical settings. We repurposed 136 
publically available datasets describing host transcriptional response in two malaria,10,16 four 137 
tuberculosis,8,17 and four dengue cohorts (Supplementary Table 2).9,18,19 We designed a discovery 138 
cohort consisting of control samples from each respective study (n=220 community controls or 139 
convalescent samples, µCTRL¶), 74 enteric fever (µEF¶), 94 blood stage P. falciparum (µbsPf¶), 67 140 
dengue (µDENV¶) and 54 active pulmonary tuberculosis (µPTB¶) cases. An independent validation 141 
cohort consisted of 109 CTRLs, 50 EF, 19 bsPf, 49 DENV, and 97 PTB samples (Figure 2).  Finally, 142 
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a cohort of µunknown¶ samples was created consisting of febrile culture-negative, febrile suspected 143 
EF cases from Nepal (µsEF¶), and samples collected from CHIM study participants who did not elop 144 
enteric fever after challenge at day 7 (µQ'¶) and their respective pre-challenge baseline samples 145 
µ'¶) (Figure 2). Using Principle Component Analysis (PCA) to assess the variability at the level of 146 
gene expression between the cohorts indicated some distinct clustering between cases 147 
(Supplementary Figure 2a), for each infection whereas no such differences were observed with the 148 
comparator CTRL samples (Supplementary Figure 2b). 149 
 150 
Five genes sufficiently distinguish EF from other febrile infections 151 
With these data, we aimed to build a classifier containing a minimum set of genes that could 152 
discriminate culture-confirmed enteric fever cases from individuals with other causes of fever (class: 153 
µ5HVW¶consisting of CTRLs, DENV, PTB and bsPf) (2-class classification, Figure 2) using a Guided 154 
Regularized Random Forest (GRRF) algorithm.20 Genes were ranked by frequency of selection in 155 
each of 100 iterations, and applying a selection threshold of ш25%, we identified a putative diagnostic 156 
signature containing STAT1 (98% of iterations), SLAMF8 (76%), PSME2 (39%), WARS (37%), and 157 
ALDH1A1 (36%) (Figure 3a). With this 5-gene signature we were able to predict which individuals 158 
in the validation cohort had enteric fever with a sensitivity and specificity of 97.1% and 88.0%, 159 
respectively (AUROC: 96.7%) (Figure 3b, Supplementary Table 3a). Of blood culture-confirmed 160 
enteric fever cases in the validation cohort, 6/51 were misclassifiHGDVµ5HVW¶i.e. classification 161 
probability>0.5, Figure 3c-top), and 8/274 VDPSOHVEHORQJLQJWRFODVVµ5HVW¶ZHre classified as 162 
enteric fever. These included six tuberculosis and one dengue case, and a pre-challenge baseline 163 
sample from a CHIM participant (Figure 3c-bottom).  164 
To allow comparison between the different disease conditions, we quantified expression of the 5 165 
genes identified in each sample using the z-score of the geometric mean of the expression values 166 
(expression score). Significant differences in expression scores were observed between the enteric 167 
fever samples and all other conditions in both the discovery (top) and the validation (bottom) cohort 168 
(Figure 3d). Of note, there were no significant differences between the scores calculated for the 169 
control samples derived from endemic areas or nave, healthy controls from the CHIM, indicating the 170 
homogeneity of expression to these genes in healthy controls from different study and geographical 171 
locations.  172 
The design of discovery and validation cohorts is likely to have an impact on the diagnostic signature 173 
selected, and we therefore exchanged the validation and discovery cohort and re-ran the analysis. 174 
Although in this experiment 4 instead of 5 genes were selected (using a threshold 25%), most genes 175 
included were also part of the initial signature (STAT1, SLAMF8, WARS) and the high predictive 176 
accuracy was maintained (AUROC: 97.2%) (Supplementary Figure 3a&b). These results 177 
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demonstrate the ability of a small number of genes to accurately predict true EF cases from other 178 
febrile illnesses caused by another bacterial pathogen (TB), and of parasitic or viral origin. 179 
 180 
Multiclass prediction accurately classifies three of five conditions simultaneously 181 
Given the apparent success of small gene expression signatures in classifying two distinct groups, we 182 
sought to leverage the overall dataset and the GRRF algorithm to identify a signature that could 183 
accurately classify more than two classes simultaneously. We re-analysed the data preserving the 184 
original class labels (i.e. CTRL, bsPf, DENV, PTB and EF) and performed the iterative feature 185 
selection step using the GRRF algorithm (Figure 2±³multiclass classification´). Applying a 25% 186 
selection threshold to ranked features identified 7 genes (RFX7, C1QB, ANKRD22, WARS, BATF2, 187 
STAT1, and C1QC) able to discriminate the classes (Figure 3e). Prediction of the validation cohort 188 
using this 7-gene signature indicated good sensitivity and specificity for accurately classifying CTRL, 189 
bsPf and EF cases, however the identification of DENV and PTB was less accurate (Figure 3f, 190 
Supplementary Table 3b). Analysis of individual gene expression levels in each group indicated that 191 
RFX7 was only upregulated in bsPf samples, while STAT1, WARS as well as ANKRD22 and BATF2 192 
were all strongly upregulated in EF. Expression of these genes in PTB and DENV samples was 193 
variable accounting for the lower performance of the signature in these conditions (Supplementary 194 
Figure 4a&b).  195 
 196 
Prediction of unknown samples  197 
Given the superior performance of the 2-class diagnostic signature, our subsequent analyses focused 198 
on using the initial 5-genes identified to ascertain whether enteric fever was the likely true underlying 199 
aetiology of suspected febrile, blood culture-negative cases in Nepal (sEF; n=71), part of the unknown 200 
cohort (Figure 2). Included in this cohort were 144 samples originating from the challenge study with 201 
known class membership confirming the correct classification of 94.4% of the samples by the GRRF 202 
algorithm (Supplementary Table 4).  203 
Classification of these sEF cases predicted 9/71 (12.6%) febrile, culture-negative patients to be true 204 
enteric fever cases and the remaining samples to belong WRFODVVµ5HVW¶Figure 4a). Relating the gene 205 
expression scores to the predicted class probabilities indicated no clear separation of scores according 206 
to the predicted class (Figure 4b). Furthermore, comparing the expression score of febrile, culture-207 
negative samples with culture confirmed enteric fever in Nepal showed a marked overlap, indicating 208 
that these scores alone are insufficient for 2-class discrimination (Figure 4c). 209 
 210 
Diagnostic validation by qPCR 211 
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Finally, to validate the induction of the diagnostic gene signature in blood culture-confirmed enteric 212 
fever cases, we performed high-throughput qPCR in samples collected during an independent typhoid 213 
CHIM (Supplementary Table 2)21 and in the Nepali cohort. Transcription of the 5-gene signature 214 
was increased at the time of diagnosis in most participants with culture-confirmed enteric fever in 215 
both sample sets (Figure 4d&e). Two CHIM participants diagnosed with typhoid infection and one 216 
patient infected with S. Paratyphi in Nepal showed low expression of all genes and a resulting low 217 
expression score (Figure 4e±black arrows). In contrast, one day 7 sample from a participant not 218 
diagnosed with enteric fever demonstrated high expression of the putative diagnostic gene signature 219 
(Figure 4e±black arrows).  220 
As surrogate disease severity markers, temperature showed poor correlation with the expression score 221 
in both CHIM and endemic setting culture-confirmed enteric fever cases (Figure 4f&g±left). In 222 
contrast, C-reactive protein levels (only available for CHIM participants) were significantly 223 
associated with the expression score of the 5-gene signature (Figure 4f&g±right) thus underlining the 224 
relevance of this signature in reflecting the clinical presentation of enteric fever. In the Nepal cohort, 225 
gene expression also strongly correlated between the array and qPCR data (Supplementary Figure 226 
6). Overall these results verify the strong expression of the putative diagnostic signatures in samples 227 
from patients with acute enteric fever and underline the clinical plausibility through association with 228 
disease severity parameters. 229 
  230 
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Discussion 231 
New approaches to diagnose patients with enteric fever are urgently needed, as currently available 232 
methods are antiquated and unreliable. New diagnostic modalities are required, to both improve the 233 
immediate management of patients, and to increase the accuracy of disease burden measurements to 234 
support targeted vaccine implementation. Here we demonstrate a reproducible host expression 235 
signature of 5 genes (STAT1, SLAMF8, PSME2, WARS, and ALDH1A1) able to discriminate EF cases 236 
from other common causes of fever in the tropics with an accuracy of >96%. To our knowledge, this 237 
exceeds the performance of all previously described enteric fever diagnostic methods, which often 238 
perform less well when assessed using samples collected directly from patients or participants. 239 
Moreover, application of high-throughput methods such as functional genomics, to this major health 240 
concern,22 underscores the importance and tangible benefits of applying µRPLFV-technologies¶to 241 
combatting infectious diseases in the most needy populations.23 While further optimisation work is 242 
required, validating the expression of our signature using conventional methods such as qPCR 243 
demonstrates feasibility of further development into an affordable diagnostic test for use in endemic 244 
settings.24 245 
The degree of perturbation of molecular responses occurring during enteric fever can be confounded 246 
by the duration of clinical illness (ranging in 12KUVWR3 days in the CHIM and patients from Nepal. 247 
, respectively) or the specific pathogen (S. Typhi or S. Paratyphi). This may hinder identification of a 248 
reproducible gene expression signature reliably expressed in various settings. The responses to S. 249 
Typhi and S. Paratyphi cases in Nepal were remarkably similar, with the majority of DE genes 250 
overlapping between the two groups, which is unsurprising given the close genetic relatedness of both 251 
pathogens.25 Enrichment of BTMs resembled responses described previously by us13,26 and underlined 252 
the concordance between culture-confirmed enteric fever cases from Oxford and Nepal despite the 253 
possible differences between challenge and currently circulating strains. 254 
Despite the multiple redundancies incorporated into human immune pathways driven by successful 255 
evolution,27 our data suggest that the pattern of immune response activation is sufficiently specific to 256 
allow identification of the causative pathogen. For example, while immune responses during enteric 257 
fever and TB are broadly characterized by IFN-signalling, we and others have reported that this 258 
response during acute S. Typhi infection appears to be skewed towards a type-II pattern likely 259 
associated with neutrophils and NK cells rather than the type-I dominated profile found in TB.7,8,13,28-260 
31 Application of computational methods to large datasets including host gene expression has been 261 
shown to be an effective approach to capture such differential activation of immune pathways.5,6 Two 262 
of the genes identified in our 5-gene diagnostic signature are important entities in the IFN-i signalling 263 
cascade (STAT1, WARS), which has been broadly implicated in the responses to enteric fever, TB,8 264 
dengue,32 and P. falciparum33 infection. The discriminatory impact of increased expression of these 265 
genes identified in our analysis, however, suggests that there are distinct differences during the 266 
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responses to these very different pathogens sufficient to discriminate underlying disease aetiology34,35 267 
possibly based on subtle metabolic differences.13,36 While STAT1 and WARS are markers of an IFN-i 268 
response, SLAMF8 is surface-expressed protein37 found in macrophages, DCs and neutrophils and 269 
induced by IFN-i or Gram-negative bacteria.38 SLAMF8 negatively regulates ROS production 270 
through inhibition of NADPH oxidase 2 (NOX2) in the bacterial phagosome and reduces ROS-271 
induced inflammatory cell migration.39 While oxidative stress is a common response to infection, 272 
Salmonella survival is reduced in SLAMF1-deficient mice and can interfere with localization of 273 
functional NOX2 in Salmonella-containing vacuoles (SCVs), linking SLAM proteins and oxidative 274 
stress.40 PSME2 is one of two interferon-inducible subunits of the 20S immunoproteasome (IP) 275 
regulator 11S and is involved in immune responses and antigen processing.41 The 20S IP can be 276 
induced by oxidative stress and preferentially hydrolyses non-ubiquitinated proteins.42,43 Thus, genes 277 
involved in these processes may be exploited to distinguish between pathogens inducing oxidative 278 
stress from those also triggering ubiquitination.44,45 While ALDH1A1 has not specifically been linked 279 
with responses to invasive bacterial infections, it is involved in gut-homing of TCs through expression 280 
of retinoic acid,46,47 a phenotype we have observed following infection with S. Typhi.26 C1QB and 281 
C1QC are well-known subunits of the complement subcomponent C1q and, together with ANKRD22 282 
(involved in cell cycle control48), have previously been described as part of a signature able to 283 
distinguish active from latent TB.17 The function of the transcription factor RFX7 is largely unknown, 284 
but has been found to be strongly up-regulated during blood stage malaria and its selection in our 7-285 
gene signature is therefore likely to be driving the classification of malaria cases.  286 
Of note, while multiclass classification is difficult to perform and here merely serves as demonstration 287 
that data driven approaches may be capable of performing this task, it is interesting to observe 288 
increased misclassification rates specifically in the DENV and TB groups. In the validation cohort, 289 
the majority of misclassified DENV cases were identified as enteric fever (5/49) or TB (9/49), and 290 
misclassified TB samples as enteric fever (13/97) or DENV (23/97), possibly reflecting the 291 
overlapping immune response seen due to the intracellular nature of all three pathogens. In the TB 292 
group, 15/97 samples were misclassified as controls, compared with one DENV sample being 293 
misclassified as such for example, potentially owing to the broad clinical phenotype or lack of 294 
inflammatory/immune responses seen in the peripheral blood during tissue specific pulmonary TB 295 
infection. 296 
Overall, the genes identified in both signatures through our unbiased selection approach are supported 297 
by previous studies including those aiming to develop predictive diagnostic signatures.8,17,49 In the era 298 
RIELRORJLFDOµELJGDWD¶VHYHUDOVWXGLHVKDYHH[SORUHGWKHutility of gene transcription signatures 299 
capable of discriminating viral aetiologies, viral or bacterial infections as well as acute or latent 300 
tuberculosis.5,6,17,50-53 Only in the tuberculosis studies have such signatures been identified from 301 
samples collected in high-incidence, disease endemic settings and been further validated against other 302 
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disease processes including (but not limited to) pneumonia, sepsis, and streptococcal and 303 
staphylococcal infections.6,8,50 Herberg et al. demonstrated that distinction between viral and bacterial 304 
infections could be achieved based on two genes only.5 In contrast most efforts undertaken to 305 
diagnose active TB employ biomarker signatures ranging in size from 3-86 genes, possibly due to 306 
broad and heterologous molecular responses seen in response to differing clinical phenotypes of 307 
infection. In our analysis we specifically focused on pathogens with the potential to cause 308 
undifferentiated febrile illnesses in tropical settings. While the clinical presentation and epidemiology 309 
of the infections chosen may be sufficient to distinguish the aetiologies clinically, enteric fever has a 310 
broad differential diagnosis and is frequently over-diagnosed in the absence of confirmatory 311 
laboratory results. Notably, despite the high prediction accuracy of the signatures identified in our 312 
analysis, this type of data modelling is highly dependent on the quality and availability of suitable 313 
input datasets. Although an increasing amount of data is accumulating in the public domain, few well-314 
defined datasets of samples representing a larger repertoire of febrile illnesses are available. For 315 
example, rickettsial infection is likely to underlie a large burden of the culture-negative cases in 316 
Nepal, however no gene expression datasets exist and the lack of adequate confirmatory diagnostic 317 
tests further hinders the inclusion of such data in our analysis. 318 
Although the 5-gene signature achieved high accuracy in identifying enteric fever cases, several 319 
culture-confirmed cases were misclassified. Metadata from samples collected in the Oxford CHIM 320 
indicate that the majority of these misclassified samples had a temperature below 37żC (5/6) and were 321 
diagnosed beyond 7 days after challenge (4/6), which, in our CHIM experience, is likely to indicate a 322 
less severe disease phenotype. In contrast, six nD7 samples from the Oxford CHIM (part of the 323 
unknown cohort) classified as enteric fever showed some sign of response either based on increased 324 
cytokines, temperature or a positive stool culture (data not shown). Because our analysis was purely 325 
data driven and not motivated by clinical suspicion, we believe that these observations and the 326 
significant association of the gene expression scores with CRP provide sufficient evidence that these 327 
study participants had infection despite not meeting our study endpoint definitions for enteric fever. 328 
In summary, our work demonstrates how a large gene expression dataset derived from challenge study 329 
cohorts and settings endemic for febrile infectious diseases can be exploited for diagnostic biomarker 330 
discovery. Verification of the putative diagnostic signature using qPCR in independent validation sets 331 
indicates that a diagnostic test derived from these gene expression data could be developed for 332 
deployment in resource-limited settings. The application of purely data-driven analyses to large and 333 
well-defined host-pathogen datasets derived from disease relevant populations may enable us to 334 
develop a single, highly accurate diagnostic signature which would allow rapid identification of the 335 
main fever-causing aetiologies from readily available biological specimens.   336 
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Online Methods 337 
Typhoid challenge model 338 
Samples included in the discovery cohort were collected during a typhoid dose-escalation study in 339 
which 41 healthy adult volunteers ingested a single dose of S. Typhi Quailes strain following pre-340 
treatment with 120 mL sodium bicarbonate solution (Study: T1). In this study, one of two doses were 341 
administered: 1-5x103 (n=21) and 1-5x104 (n=20).4 Samples used in the validation cohort were 342 
collected from a second typhoid challenge model performed as part of a vaccine efficacy study 343 
(Study: T2), in which healthy adult volunteers ingested a single dose of S. Typhi Quailes strain (1-344 
5x104, n=99) 4 weeks after oral vaccination with Ty21a, M01ZH09 or placebo.54 Lastly, samples 345 
collected from the control arm of a further vaccine efficacy challenge study, in which participants 346 
received meningococcal ACWY-CRM conjugate vaccine (MENVEO¨, GlaxoSmithKline) prior to 347 
challenge, were used for the independent qPCR validation experiment.21 The clinical and molecular 348 
results of these studies have been described previously.4,7,21,54 In all typhoid challenge studies 349 
participants were treated with a 2-week course of antibiotics at the time of diagnosis (fever 38¡C 350 
sustained for 12hrs and/or positive blood culture), or at day 14 post-challenge if diagnostic criteria 351 
were not reached. 352 
 353 
Paratyphoid challenge model 354 
Clinical samples for paratyphoid infection were collected during a dose-escalation study, as 355 
previously described (P1).7 Briefly, 40 healthy adult volunteers were challenged with a single oral 356 
dose of virulent S. Parayphi A (strain NVGH308) bacteria, which as before, was suspended in 30mL 357 
sodium bicarbonate solution [17.5mg/mL], and after pre-treatment with 120mL sodium bicarbonate 358 
solution. Oral challenge inocula was given at one of two dose levels, low (n=20; median 359 
[range]=0.9!103 CFU [0.7!103±1.3!103]) or high dose (n=20; median [range]=2.4!103 CFU 360 
[2.2!103±2.8!103). Criterion for diagnosis were either PLFURELRORJLFDOSRVLWLYHEORod culture 361 
collected after day 3) and/or clinical (fever 38¡C sustained for 12hrs). Participants were ambulatory 362 
and followed up as outpatients at least daily after challenge when safety, clinical, and laboratory 363 
measurements were performed.7 364 
 365 
Endemic Cohort 366 
To validate the gene transcriptional signatures in a relevant patient cohort, blood samples were 367 
collected from three cohorts at Patan Hospital or the Civil Hospital both located in the Lalitpur Sub-368 
Metropolitan City area of Kathmandu Valley in Nepal. Firstly, blood samples were collected as part 369 
of a diagnostics study55 from febrile patients presenting to hospital and diagnosed with blood culture-370 
confirmed S. Typhi (n=19) or S. Paratyphi A (n=12) infection and febrile patients who were blood 371 
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culture negative (n=71). Samples from a cohort of healthy control volunteers (n=44) were also 372 
collected as part of this study.  373 
 374 
Gene expression arrays sample processing 375 
In the human challenge studies (T1, T2, and P1), peripheral venous blood (3mL) was collected in 376 
TempusTM Blood RNA tubes (Applied Biosystems) before challenge (baseline, pre-challenge controls, 377 
µ'¶n=166DQGDWSDUDW\SKRLGGLDJQRVLVµ637¶n RUW\SKRLGGLDJQRVLVµ67¶Q ,QWKRVH378 
challenged but who did not develop enteric fever within 14 days of challenge, gene expression was 379 
measured at the median day of diagnosis of the diagnosed group in the appropriate studies and this 380 
GD\ZDVWHUPHGµQ'¶n=73). In Nepal, blood was collected when patients presented to hospital 381 
(n=102) and from healthy controls (n=44) (Figure 1A, Supplementary Table S1). Total RNA was 382 
extracted from all samples using the TempusTM Spin RNA Isolation kit (Life Technologies). Where 383 
applicable, 50ng of RNA was used for hybridization into Illumina HT-12v4 bead-arrays (Illumina 384 
Inc.) at the Wellcome Trust Sanger Institute (Hinxton, UK) or The Wellcome Trust Centre for Human 385 
Genetics (Oxford, UK) and fluorescent probe intensities captured with the GenomeStudio software 386 
(Illumina Inc.). For the paratyphoid CHIM (P1) RNA gene expression was determined using RNA 387 
sequencing. Briefly, libraries were prepared using a poly-A selection step to exclude ribosomal RNA 388 
species (read length: 75bp paired-end) and samples were subsequently multiplexed in 95 samples/lane 389 
over 10 lanes plus one 5-plex pool run on 1 lane and sequenced using a Illumina HiSeq 200 V4. 390 
Data pre-processing 391 
Paired-end reads were adapter removed and trimmed from 75 to 65bp using trimmomatic v0.3556 and 392 
only reads exceeding a mean base quality 5 within all sliding windows of 5bp were mapped to the 393 
Gencode v25/hg38 transcriptome using STAR aligner v2.5.2b keeping only multi mapped reads 394 
mapping to at most 20 locations. featureCounts from the subread set of tools v1.5.1 was used to 395 
quantify reads in Gencode v25 basic gene locations with parameters  -C -B -M -s 2 -p -S fr. Between-396 
sample normalization was performed using TMM (Trimmed Mean of M-values) normalization as 397 
implemented in the edgeR57 package and we used principle component analysis (PCA) as quality 398 
control step and excluded 2 samples, which were clear outliers due to also failing QC during the 399 
library preparation. Counts were converted into log2 counts per million (cpm) values with 0.5 prior 400 
counts to avoid taking the logarithm of zero and were then taken forward to the multi-cohort quality 401 
control. Illumina HT-12v4 bead array data were pre-processed by background subtraction, quantile 402 
normalization and log2-transformation using the limma package in R.
58 Probes were collapsed to 403 
HUGO gene identifiers keeping only the highest expressed probe. 404 
Data download 405 
Previously published whole blood transcriptional array data was downloaded from the Gene 406 
Expression Omnibus (GEO) data repository. In this study we specifically focused on studies 407 
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investigating blood stage Plasmodium falciparum (bsPf; two cohorts of blood-stage, HIV-negative 408 
malaria cohorts; children and adults),10,16 acute uncomplicated dengue (DENV; four adult South-East 409 
Asian cohorts of uncomplicated dengue fever patients),9,18,19 and active pulmonary tuberculosis (PTb; 410 
four cohorts of active, pulmonary TB HIV-negative adults from Africa and the UK),8,17 all infections 411 
which present with undifferentiated fever and are relevant to areas where enteric fever is endemic 412 
(Supplementary Table S2). Raw data were downloaded from GEO using the getGEO-function59 and 413 
quantile normalization with detection p-values and control probes where available. Probes were 414 
collapsed to HUGO gene identifiers keeping only the highest expressed probe. 415 
Data processing and cohort Quality Control 416 
Probe sequences on microarrays may not correspond to the most recent release of the human reference 417 
genome that was used for the RNAseq alignment. In order to mitigate this potential discrepancy we 418 
re-annotated the probes to the Gencode v25/hg38. The new annotations were used as gene names for 419 
each probe. To avoid uninformative genes and gender bias only probes common to all datasets, not 420 
located on sex chromosomes and with an expression above the lowest tertile of the average expression 421 
(12,821 probes) were used and a µVXSHUVHW¶was created by merging the expression data from all 422 
studies into one large data matrix. In order to avoid platform or study related artefacts between the 423 
data we applied surrogate variable analysis (sva)60 to remove batch effects based on study ID while 424 
preserving the disease condition (i.e. control or individual infection). 425 
Diagnostic signature identification 426 
For classification analyses, we separated the superset into a discovery cohort and a validation cohort. 427 
To ensure heterogeneity and optimal feature identification we restricted the discovery cohort to 428 
samples solely generated on Illumina platforms and ensured inclusion of EF samples from Oxford and 429 
Nepal. In order to establish a validation cohort we casted a wider net and permitted studies generated 430 
on other platforms including Affymetrix due to the limited amount of suitable datasets available in the 431 
public domain. In addition, to predict unknown samples by applying the signatures identified in this 432 
study, we separated the febrile, culture-negative suspected enteric fever cases, samples at day 7 after 433 
challenge of those who stayed well and their respective pre-challenge control samples from the 434 
superset into a cohort of samples of unknown aetiology (Unknown Cohort) (Figure 2). 435 
Only the discovery cohort was used for feature selection using Guided Regularized Random Forest 436 
(GRRF)20 as implemented in the R package RRF v1.761 with gamma = 0.5 and parameter mtry tuning 437 
was performed using the tuneRRF command. Feature selection was repeated on 100 iterations of 438 
bootstrapped subsets of about 70% of the data in the discovery cohort. To assess model performance, 439 
predictions on the held out 30% of the discovery cohort were performed and balanced accuracies62 440 
were recorded to account for class imbalances. Genes were then ranked by the frequency of positive 441 
gene selection by GRRF (based on mean Gini) during the 100 iterations and only genes included in at 442 
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least 25% of the selection rounds were included in the diagnostic signature and used for prediction of 443 
the independent validation cohort as well as the samples belonging to the unknown cohort (Figure 2). 444 
High-throughput qPCR validation 445 
We performed TaqMan gene expression assays to validate gene expression levels in samples from 446 
Nepal and a subset of individuals from the Oxford challenge studies. A panel of 24 probes were 447 
measured in triplicates on a 192.24 Fluidigm chip using the Biomark at the Weatherall Institute for 448 
Molecular Medicine (WIMM) single cell facility. Four samples and one probe failed in the quality 449 
control and were removed from the analysis. Raw Ct values were normalized to the housekeeping 450 
gene cyclophilin A (PPIA) (FCt values) and subsequently to control samples (healthy controls) to 451 
achieve FFCt values. 452 
Statistical analysis 453 
All data were processed in R version 3.2.4. Comparison of groups in Figure 3d were performed using 454 
6WXGHQW¶VW-Test and correlations between clinical parameters and expression scores were performed 455 
using Pearson correlation and correlation between array and qPCR expression as performed using 456 
Spearman correlations (alternative: two-sided). 457 
Data deposition: 458 
The datasets generated in these studies were deposited at GEO: GSE113867. 459 
  460 
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Figure Legends and Figures: 646 
Figure 1: Overview of Oxford and Nepal comparison. (a) Overview of enteric fever cohorts used 647 
in this study (T1: Typhoid CHIM study 1; T2: Typhoid CHIM study 2; P1: Paratyphoid CHIM; 03NP: 648 
Nepali cohort. ST: S. Typhi; SPT: S. Paratyphi; sEF: suspected Enteric Fever; D0: day of challenge 649 
which represents the control samples in the Oxford CHIM; CTRL: endemic community controls; 650 
nD7: day 7 after challenge in participants who stayed well in the CHIM; BC+: Blood-culture positive; 651 
BC-: Blood-culture negative; Dx: Diagnosis). (b) Volcano plots of up (red) and down (blue) regulated 652 
genes in S. Typhi and S. Paratyphi positive individuals (Nepal and Oxford). Black numbers indicate 653 
the up- and down-regulated genes. (c) Circular plot depicting the overlap of BTMs between enteric 654 
fever and nD7 samples from Oxford and Nepal. Tracks (from outer to inner): cohort and samples; 655 
BTM labels; direction of enrichment (blue: down; red: up). Cords represent overlap of enrichment in 656 
given cohorts (red: overlap between P1-SPT and T1-ST; green: overlap between T1-nD7 and P1-nD7; 657 
blue: overlap of 03NP-ST with P1-SPT and T1-ST; purple: overlap of 03NP-SPT with P1-SPT and 658 
T1-ST; yellow: overlap between 03NP-SPT and 03NP-ST). (d-e) Scatter plots of BTMs enriched 659 
(p>0.05) in blood-culture positive samples in Nepal (y-axis) versus Oxford (x-axis) for typhoid fever 660 
(d) and paratyphoid fever (e). (f) Single-sample GSEA Normalised Enrichment Scores (NES) of IFN 661 
and DC BTMs of individuals with blood-culture confirmed enteric fever in Nepal and Oxford. (g) 662 
Heatmap of the 500 most variably expressed genes in samples of the Nepali cohort. Bar graph on top 663 
of the heatmap shows temperature of each individual at the time of sampling.  664 
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Figure 2: Flow diagram of machine learning analysis. The discover cohort consisted of only 665 
Illumina datasets and was used for feature selection using the GRRF algorithm. For the validation 666 
cohort Affymetrix datasets were also included. A cohort of unknown samples consisted of pre-667 
challenge baseline samples of participants who stayed well following challenge, their respective nD7 668 
samples (7 days after challenge), and febrile, culture-negative suspected enteric fever (sEF) cases 669 
from Nepal. Refer to Supplementary Table S2 for study identifiers. 03NP: Nepali cohort. T1: Oxford 670 
typhoid CHIM study 1. T2: Oxford typhoid CHIM study 2; P1: Oxford paratyphoid CHIM. 671 
predict	
Test	
30%	of	
samples	
Discovery	Cohort	
Illumina	data	sets		
GSE34404,	GSE19491,	GSE28991,	GSE25001,	03NP,	T1,	P1)	
Discovery	70%	
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Febrile,	culture	negaSve;	
Exposed,	not	diagnosed	
Apply	Classiﬁer	
*	Two	diﬀerent	approaches	chosen:		
2-class:	Enteric	fever	(typhoid	and	paratyphoid;	EF)	versus	the	rest.	
MulSclass:	Simultaneously	diﬀerenSaSon	between	all	classes	(EF,	bsPf,	DENV,	PTB,	CTRL).	
23 
 
Figure 3: Identification of diagnostic signatures. (a) Ranking of genes by their selection frequency 672 
into the diagnostic signature out of 100 iterations during the 2-class classification. A cut-off of 25% 673 
was selected to detect 5-gene putative diagnostic signature (orange bar). (b) Performance of the 5-674 
gene classifier when predicting the class membership of the validation cohort. (c) Top: Probability of 675 
an EF sample to be classified as non-EF (>0.5). Bottom: ProbDELOLW\RIVDPSOHEHORQJLQJWRµUHVW¶WR676 
be classified as EF (>0.5). (d) Combined expression score for samples based on the 5-gene signature 677 
for samples in the discovery cohort (top) and validation cohort (bottom). Ox.CTRL: Oxford controls 678 
(D0); CTRL: Nepali control samples. PTB: pulmonary TB; DENV: Dengue samples; bsPf: blood-679 
stage P. falciparum; SPT: S. Paratyphi; ST: S. Typhi. (e) Ranking of genes by their selection 680 
frequency into the diagnostic signature out of 100 iterations during the multiclass classification. A 681 
cut-off of 25% was selected to detect a 7-gene putative diagnostic signature (orange bar). (f) 682 
Classification probabilities for each sample of the validation cohort based on the 7-gene signature. 683 
Significance OHYHOVLQSDQHOGZHUHGHWHUPLQHGXVLQJWKH6WXGHQW¶Vt-Test: *p<0.05; **p<0.01; 684 
****p<0.0001.  685 
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Figure 4: Prediction of Nepali unknown samples using the 2-class and qPCR validation. (a) PCA 686 
of sEF samples based on the 5-gene signature coloured by predicted class membership (EF: purple; 687 
green: rest). (b) Dot plot of prediction probability of being class EF versus the expression score 688 
calculated on the bases of the 5-gene signature. (c) qPCR gene expression scores of the 5-gene 689 
signature (FFCT over PPIA) for CTRLs, sEF, SPT and ST samples from Nepal. Yellow diamonds in 690 
the sEF category represent the 9 patients classified as EF based on the RF algorithm. (d) qPCR 691 
expression values (FFCt over PPIA) of the 5-gene signature in control samples (Oxford and Nepal), 692 
samples at day 7 after challenge of participants who stayed well following challenge with S. Typhi 693 
(nD7), S. Paratyphi (SPT) or S. Typhi (ST) in Nepal, or typhoid diagnosis after challenge (TD). 694 
Colour legend in panel (e). (e) Combined qPCR expression score of the 5-gene signature. Black 695 
arrows indicate outlier samples. (f) Temperature and CRP for samples of which data was available 696 
(CRP was only measured in the Oxford CHIM). (g) 6SHDUPDQ¶VUDQNForrelation of the 5-gene 697 
combined expression score and temperature (left; only nD7 and TD samples from the Oxford CHIM 698 
and SPT and ST cases from Nepal were included) and CRP (right; CRP was only available for Oxford 699 
CHIM samples and we excluded D0 baseline measures) at presentation to hospital (Nepal), diagnosis 700 
(Oxford CHIM) or day 7 after challenge in those who stayed well (Oxford CHIM).  701 
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Supplementary Figure Legends 702 
Supplementary Figure 1: Differentially expressed genes and BTMs of sEF cases from Nepal. (a) 703 
Volcano plot of differentially expressed genes in the Nepali sEF cohort. (b) Venn diagram 704 
representing the overlap of DE genes in the Nepali ST, SPT and sEF cases. (c) ssGSEA heatmap of 705 
BTMs significantly expressed (p<0.05) in at least 60% of sEF samples. Bar plot panel represents the 706 
interdecile range (IDR) for each BTM across all sEF cases. NES: Normalized Enrichment Score. 707 
Supplementary Figure 2: Superset quality control. (a) PCA plot based on the 500 most variable 708 
genes (IQR) of enteric fever cases (EF), malaria cases (bsPf), dengue cases (DENV) and TB cases 709 
(PTB) after batch correction. (b) PCA of all control samples for each disease cohort after batch 710 
correction. 711 
Supplementary Figure 3: Signature identification using a re-designed discovery and validation 712 
cohort. (a) Ranking of genes by their selection frequency into the diagnostic signature out of 100 713 
iterations during the 2-class classification. A cut-off of 25% was chosen to detect a putative diagnostic 714 
signature consisting of 4 genes (orange bar). (b) Prediction of the validation cohort using the 4 genes 715 
identified in (a). 716 
Supplementary Figure 4: Expression of the 7 target genes identified during the multiclass 717 
classification analysis in each sample of the discovery (a) and validation cohort (b). 718 
Supplementary  Figure 5: Prediction of Oxford CHIM samples part of the unknown cohort. (a) 719 
PCA of Oxford pre-challenge baseline samples and nD7 samples based on the expression values for 720 
the 5-gene diagnostic signature (2-class classification) coloured by predicted class membership 721 
(green: REST, purple: EF). (b) Dot plot of prediction probabilities against a combined expression 722 
score for each sample coloured by predicted class membership. 723 
 Supplementary Figure 6: Spearman correlation of expression values of the 5-gene diagnostic 724 
signature derived from microarrays or qPCR. 725 
 726 
Supplementary Tables: 727 
Supplementary Table 1: Overlap of BTMs between different study groups (in percent). 728 
Supplementary Table 2: Datasets included in this study. 729 
Supplementary Table 3. (a) Contingency table of class membership following the 2-class 730 
classification. (b) Contingency table of class membership following the multiclass classification. 731 
26 
 
Supplementary Table 4: Prediction accuracy and overview of misclassified samples following 732 
prediction using the 5-gene 2-class signature of the Oxford samples included in the unknown cohort. 733 
Supplementary Table 5: Class memberships of Oxford CHIM and Nepali samples included in the 734 
unknown cohort following the prediction using the 7-gene multiclass signature. 735 
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